Merck EVP exercises 52,847 options, sells shares
Merck & Co., Inc. executive David Michael Williams, EVP and Chief Information & Digital Officer, exercised stock options covering 52,847 shares of common stock on August 5, 2026 at strike prices of $77.6200, $75.3600 and $73.7300 per share.
Rhea-AI Filing Summary
Merck & Co., Inc. executive David Michael Williams, EVP and Chief Information & Digital Officer, exercised stock options covering 52,847 shares of common stock on August 5, 2026 at strike prices of $77.6200, $75.3600 and $73.7300 per share. He then sold all 52,847 shares at a weighted average price of $128.7707, with individual sale prices ranging from $128.7050 to $128.9700.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 4,600 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F4 | 13,542 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3, F5 | 34,705 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,600 | $77.62 | $357K |
| Sale | Common Stock F1 | 4,600 | $128.7707 | $592K |
| Exercise | Common Stock | 13,542 | $75.36 | $1.02M |
| Sale | Common Stock F1 | 13,542 | $128.7707 | $1.74M |
| Exercise | Common Stock | 34,705 | $73.73 | $2.56M |
| Sale | Common Stock F1 | 34,705 | $128.7707 | $4.47M |
Footnotes (5)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2. The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022.
- F3. Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- F4. The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
- F5. The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.
Key Figures
Key Terms
weighted average price financial
spin-off financial
intrinsic value financial
distribution date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Merck (MRK) executive David Michael Williams report?
Did any corporate actions affect the option terms in this Merck (MRK) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.